Hunza Ventures
VC Fund
Luxembourg, Luxembourg
Hunza Ventures is a venture capital firm incorporated in 1998 in Luxemburg. The firm has focused its investments on early and mid-stage life sciences and IT companies with outstanding growth prospects.Hunza Ventures has built a large and well-balanced portfolio based on the strong entrepreneurial experience of the fund’s shareholders andmanagers. Since inception, Hunza Ventures has backed 20 companies in Belgium, Israel, USA and Singapore.Hunza Ventures has raised two funds:Hunza Ventures raised €15 million. The fund made 14 venture investments and is fully invested. A series of companies have successfully been divested.Hunza Ventures II raised €6.25 million in October 2008. This fund is actively investing and is currently raising additional capital.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Hunza Ventures invests in
Stages Hunza Ventures invests in
Countries Hunza Ventures invests in
Investment Focus
Industry
- Medical 2 (100%)
- Health Care 2 (100%)
- Biotechnology 2 (100%)
- Pharmaceutical 1 (50%)
Stage
- Series A 1 (50%)
- Funding Round 1 (50%)
Country
- Belgium 1 (50%)
- United States 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ITeos Therapeutics is a private biotechnology company targeting the metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology,therapeutic cancer vaccines, cancer biology, and translational medicine in cancer.iTeos endeavors to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies). | $9.9M / Series A / May 03, 2012 | ||
| Formac is a spin-off company from the University of Leuven, Belgium (K.U.Leuven), from which it has obtained the exclusive and worldwide rights to develop and commercialise ordered mesoporous silica materials for the delivery of poorly soluble API's. The company was incorporated on 3 October 2007 and is privately owned. The main shareholdersof Formac are K.U.Leuven, Allegro Investment Fund, Hunza Ventures, Gemma Frisius Fonds K.U.Leuven, Vinnof PMV and Life Sciences Research Partners VZW (formerly D. Collen Foundation).Since its incorporation Formac has signed more than 40 feasibility agreements with Tier 1 Pharma companies and SMEs in the field of human and veterinary medicine. To date, Formac is the only company that demonstrated the clinical relevancy of the silica based technology in a clinical setting. | $1.9M / Nov 08, 2007 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Hunza Ventures invest in?
Hunza Ventures invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Hunza Ventures last invest?
The most recent investment recorded for Hunza Ventures closed in May 2012. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
